Dr. Yoon is an Assistant Professor at the University of Utah Rocky Mountain Center for Occupational and Environmental Health. Her responsibilities include research, teaching, administration, and patient care. She is board-certified in Occupational Medicine. She has performed research on lateral epicondylitis of a large prospective cohort study and on the health and wellness of firefighters, specifically focusing on the topic of obesity. Currently, she is performing research on a large prospective cohort study on COVID-19 vaccine effectiveness in essential and frontline workers with Centers for Disease Control and Prevention (CDC). She is also conducting a clinical trial on influenza vaccine efficacy with the CDC. She enjoys teaching and mentoring and looks forward to the opportunity to further develop this aspect of scholarship in her career. She is the course director for OEHS 6504 Clinical and Behavioral Aspects of Preventive Medicine. She is the Assistant Program Director for the Occupational Medicine Residency. In addition to her clinical and academic responsibilities, she serves as a medical director/occupational health specialist and has various other administrative roles.
Education History
| Chief Resident |
University of Utah School of Medicine Occupational Medicine |
Chief Resident |
|---|---|---|
| Graduate Training |
University of Utah School of Medicine Occupational Health |
M.O.H. |
| Residency |
University of Utah School of Medicine Occupational Medicine |
Resident |
| Internship |
West Anaheim Medical Center Internal Medicine |
Intern |
| Professional Medical |
Touro University Nevada College of Osteopathic Medicine Osteopathic Medicine |
D.O. |
| Certification |
University of California, Los Angeles Pre-Medical and General Science Studies |
Certificate |
| Undergraduate |
University of California, Los Angeles Spanish |
B.A. |
Selected Publications
- Yoon SK, Burgess JL, Olsho LE, HEROES-RECOVER Network Investigators (2022). Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers [Letter to the editor]. New England Journal of Medicine (International Edition), 386(19), 1855-1857.
- Fowlkes AL, Yoon SK, Lutrick K, et al (2022). Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep, 71(11), 422-428.
- Burns J, Rivers P, LeClair LB, Yoon SK, Fowlkes AL, Naleway AL, Gwynn L, Burgess JL, Thompson MG, Olsho LE, Gaglani M (In Press (Preprint)). Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study. JMIR Res Protoc.
- Lutrick K, Groom H, Fowlkes AL, Groover K, Nguyen K, Rivers P, Parker J, Herring M, Prather K, Baccam Z, Lamberte JM, Dunnigan K, Naleway AL, Phillips AL, Thiese MS, Gaglani M, Tyner H, Yoon SK (2022). COVID-19 Vaccine Perceptions and Uptake in a National Prospective Cohort of Essential Workers. Vaccine, 40(3), 494-502.
- Naleway AL, Grant L, Caban-Martinez AJ Yoon SK, Tyner HLJones JM, Mistry P, Thompson MG, Fowlkes AL (2022). Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses.
- Lutrick K, Rivers P, Yoo YM, Yoon SK, Meece J, Gaglani M, Burns J, Mayo Lamberte J, Nakayima Miiro F, Bissonnette A, LeClair L, Kutty PK, Romine JK, Stefanski E, Edwards LJ, Ellingson K, Gerald JK, Bedrick EJ, Madhivanan P, Krupp K, Gerald LB, Thompson M, Burgess JLK (2021). Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021. MMWR Morb Mortal Wkly Rep, 70(5152), 1761-1765.
- Tyner HL, Burgess JL, Grant MS, Gaglani M, Kuntz JL, Naleway AL, Thornbug N, Caban-Martinez A, Yoon SK, Blanton L, Nikolich-Zugich J, Fowlkes AL, Thiese MS, et al (2021). Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of Natural Infection. Clin Infect Dis.
- Edwards LJ, Fowlkes AL, Wesley MGYoon SK, Tyner HL, Burgess JL, Hunt DR, Meece J, Gaglani M, Naleway AL, Thompson MG (2021). Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): study design and methods for a multi-site longitudinal cohort . JMIR Res Protoc.
- Thompson MG, Grant L, Meece J, HEROES-RECOVER Network (2021). Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply. [Letter to the editor]. New England Journal of Medicine (International Edition), 385(19), 1819-1821.
- Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, HEROES-RECOVER Network (2021). Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021. MMWR Morb Mortal Wkly Rep, 70(34), 1167-1169.
- Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, et al (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. New England Journal of Medicine (International Edition), 385(4), 320-329.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, et al (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep, 70(13), 495–500.
- Mumenthaler S, Yoon NK, Li A, Mah V, Chang G, Nooraie F, Elshimali Y, Hanna S, Kim S, Horvath S, Apple S, Chia D, Seligson DB, Goodglick L (2008). Tissue Microarrays: Construction and Utilization For Biomarker Studies. In Hayat MA (Ed.), Methods of Cancer Diagnosis, Therapy, and Prognosis. Springer.